Economic evaluations using QALYs are necessary to fully assess the value of rotavirus vaccination in Europe by accounting for both reduced costs and morbidity.
No takes yet. Share an insight, caveat, or question.
QALY-based evaluations may inform rotavirus vaccine investment decisions; leaves open standardization for European policy adoption.
Rheingans et al. (2006) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: